SCHEMBL4914520

SCHEMBL4914520

CC(C)(C)c1n[nH]cc1CNC(=O)c1ccc(-c2ccccn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.52
PPARG P37231 1/20 0.47
ABL1 P00519 1/20 0.46
BCR P11274 1/20 0.46
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46
HPGDS O60760 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TGFBR1 P36897 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42
HTT P42858 1/20 0.41
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
DRD3 P35462 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4914529 0.83 ROCK2 (0.53) LMNAKMT2AHTT
SCHEMBL3635014 0.81 TRPV1 (0.43) TRPV1
SCHEMBL14082164 0.77 HTT (0.71) LMNAPOLBHTTHTR1ADRD2
SCHEMBL17704486 0.77 TRPV1 (0.67) TRPV1ABL1BCRLMNARAB9A
SCHEMBL4914813 0.76 TP53 (0.46) POLB
SCHEMBL4918266 0.76 NPC1 (0.44) NPC1LMNARAB9AHTT
SCHEMBL14082200 0.74 LMNA (0.79) NPC1LMNAPOLBRAB9AHPGDS
SCHEMBL14082179 0.74 HPGDS (0.73) NPC1LMNAPOLBRAB9AHPGDS
SCHEMBL4911611 0.74 GAA (0.47) PPARGLMNAKMT2AHTTHPGD
SCHEMBL14082207 0.74 TRPV1 (0.58) TRPV1PPARGABL1BCRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 TRPV1 164/4885PPARG 175/4885ABL1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.